Adaptimmune Therapeutics (Adaptimmune Therapeutics) FCF Yield % : -53.06 (As of Apr. 27, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Adaptimmune Therapeutics's Trailing 12-Month Free Cash Flow is $-145.76 Mil, and Market Cap is $274.73 Mil. Therefore, Adaptimmune Therapeutics's FCF Yield % for today is -53.06%.

The historical rank and industry rank for Adaptimmune Therapeutics's FCF Yield % or its related term are showing as below:

ADAP' s FCF Yield % Range Over the Past 10 Years
Min: -175.03 Med: -17.02 Max: 0.69
Current: -53.06

During the past 12 years, the highest FCF Yield % of Adaptimmune Therapeutics was 0.69%. The lowest was -175.03%. And the median was -17.02%.

ADAP's FCF Yield % is ranked worse than
75.35% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs ADAP: -53.06

Adaptimmune Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -6,711.26%.

Adaptimmune Therapeutics FCF Yield % Historical Data

The historical data trend for Adaptimmune Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics FCF Yield % Chart

Adaptimmune Therapeutics Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-91.59

-6.77

0.33

-71.40

-80.91

Adaptimmune Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-2.31	-88.20	-86.38	-102.70	-34.42

Competitive Comparison of Adaptimmune Therapeutics's FCF Yield %

For the Biotechnology subindustry, Adaptimmune Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's FCF Yield % falls into.

Adaptimmune Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Adaptimmune Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-145.76	/	180.144224
	=	-80.91%

Adaptimmune Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-15.503	*	4	/	180.144224
	=	-34.42%

Adaptimmune Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Adaptimmune Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

473A:Germany

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

Executives

Elliot Norry	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Bertrand William C Jr	officer: Chief Operating Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
John Lunger	officer: Chief Patient Supply Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Adrian Rawcliffe	officer: Chief Financial Officer	440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146
Kristen Hege	director	500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070
Garry E Menzel	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Priti Hegde	director	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Andrew R Allen	director	2525 28TH STREET, SUITE 200, BOULDER CO 80301
Cintia Piccina	officer: Chief Commercial Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Gavin Wood	officer: Chief Financial Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Joanna Elizabeth Brewer	officer: Chief Scientific Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Helena Katrina Tayton-martin	officer: Chief Operating Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James Noble	director, officer: Chief Executive Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX